Increased HCMV seroprevalence in patients with hepatocellular carcinoma

Virology Journal

Volumn 8, Issue , 2011, Pages

  Lepiller, Quentin ^a   Tripathy, Manoj K ^a   Di Martino, Vincent ^b   Kantelip, Bernadette ^c   Herbein, Georges ^a  

^a UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^b Université Bourgogne Franche Comté   (France)

^c UNIVERSITY HOSPITAL OF BESANÇON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; VIRUS DNA;

ADULT; ARTICLE; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; FEMALE; GROUPS BY AGE; HISTOPATHOLOGY; HOSPITALIZATION; HUMAN; HUMAN CYTOMEGALOVIRUS; HUMAN TISSUE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; POLYMERASE CHAIN REACTION; PROTEIN BLOOD LEVEL; SEROPREVALENCE; SEX DIFFERENCE; VIRUS DETECTION; ADOLESCENT; AGED; BIOPSY; BLOOD; CHILD; COMORBIDITY; CYTOMEGALOVIRUS; EPIDEMIOLOGY; FRANCE; HEPATITIS B VIRUS; HEPATITIS C VIRUS; ISOLATION AND PURIFICATION; LIVER; MIDDLE AGED; MIXED INFECTION; PATHOLOGY; PRESCHOOL CHILD; UNIVERSITY HOSPITAL; VIROLOGY;

HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN HERPESVIRUS 5;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOPSY; CARCINOMA, HEPATOCELLULAR; CHILD; CHILD, PRESCHOOL; COINFECTION; COMORBIDITY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; FRANCE; HEPACIVIRUS; HEPATITIS B VIRUS; HOSPITALS, UNIVERSITY; HUMANS; INTERLEUKIN-6; LIVER; MALE; MIDDLE AGED; SEROEPIDEMIOLOGIC STUDIES;

EID: 80054961706     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-8-485     Document Type: Article

References (61)

1. Circulating tumor necrosis factor, interleukin-1 and interleukin-6 concentrations in chronic alcoholic patients. Khoruts A, Stahnke L, McClain CJ, Logan G, Allen JI, Hepatology 1991 13 267 276 1995437
2. Serum interleukin 6 levels in patients with chronic hepatitis B. Kakumu S, Shinagawa T, Ishikawa T, Yoshioka K, Wakita T, Ito Y, Takayanagi M, Ida N, Am J Gastroenterol 1991 86 1804 1808 1962626
3. Serum interleukin 6 concentrations in chronic hepatitis C patients before and after interferon-alpha treatment. Malaguarnera M, Di Fazio I, Laurino A, Ferlito L, Romano M, Trovato BA, Int J Clin Pharmacol Ther 1997 35 385 388 9314092 (Pubitemid 27417679)
4. Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma. Soresi M, Giannitrapani L, D'Antona F, Florena AM, La Spada E, Terranova A, Cervello M, D'Alessandro N, Montalto G, World J Gastroenterol 2006 12 2563 2568 16688802
5. [Role of interleukin 6 in hepatocellular carcinoma]. Malaguarnera M, Di Fazio I, Laurino A, Romeo MA, Giugno I, Trovato BA, Bull Cancer 1996 83 379 384 8680090
6. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Naugler WE, Karin M, Trends Mol Med 2008 14 109 119 10.1016/j.molmed.2007.12.007 18261959
7. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, Osterreicher CH, Takahashi H, Karin M, Cell 2010 140 197 208 10.1016/j.cell.2009.12.052 20141834
8. Mixed cytomegalovirus glycoprotein B genotypes in immunocompromised patients. Coaquette A, Bourgeois A, Dirand C, Varin A, Chen W, Herbein G, Clin Infect Dis 2004 39 155 161 10.1086/421496 15307021 (Pubitemid 38971482)
9. Bcl-3-regulated transcription from major immediate-early promoter of human cytomegalovirus in monocyte-derived macrophages. Khan KA, Coaquette A, Davrinche C, Herbein G, J Immunol 2009 182 7784 7794 10.4049/jimmunol.0803800 19494302
10. Cytomegalovirus cell tropism. Sinzger C, Digel M, Jahn G, Curr Top Microbiol Immunol 2008 325 63 83 10.1007/978-3-540-77349-8-4 18637500
11. Interaction of human cytomegalovirus with monocytes/macrophages: a love-hate relationship. Michelson S, Pathol Biol (Paris) 1997 45 146 158 (Pubitemid 27141743)
12. In situ production of interleukin-6 within human lung allografts displaying rejection or cytomegalovirus pneumonia. Humbert M, Delattre RM, Fattal S, Rain B, Cerrina J, Dartevelle P, Simonneau G, Duroux P, Galanaud P, Emilie D, Transplantation 1993 56 623 627 10.1097/00007890-199309000-00024 8212159 (Pubitemid 23293027)
13. Elevated serum cytokines are associated with cytomegalovirus infection and disease in bone marrow transplant recipients. Humar A, St Louis P, Mazzulli T, McGeer A, Lipton J, Messner H, MacDonald KS, J Infect Dis 1999 179 484 488 10.1086/314602 9878035 (Pubitemid 29086653)
14. Altered cellular mRNA levels in human cytomegalovirus-infected fibroblasts: viral block to the accumulation of antiviral mRNAs. Browne EP, Wing B, Coleman D, Shenk T, J Virol 2001 75 12319 12330 10.1128/JVI.75.24.12319- 12330.2001 11711622 (Pubitemid 33115904)
15. Cytomegalovirus induction of interleukin-6 in lung fibroblasts occurs independently of active infection and involves a G protein and the transcription factor, NF-kappaB. Carlquist JF, Edelman L, Bennion DW, Anderson JL, J Infect Dis 1999 179 1094 1100 10.1086/314734 10191209 (Pubitemid 29196487)
16. Cytomegalovirus modulates interleukin-6 gene expression. Geist LJ, Dai LY, Transplantation 1996 62 653 658 10.1097/00007890-199609150-00020 8830832 (Pubitemid 26313911)
17. Transcriptome analysis reveals human cytomegalovirus reprograms monocyte differentiation toward an M1 macrophage. Chan G, Bivins-Smith ER, Smith MS, Smith PM, Yurochko AD, J Immunol 2008 181 698 711 18566437
18. Human cytomegalovirus activates inflammatory cytokine responses via CD14 and Toll-like receptor 2. Compton T, Kurt-Jones EA, Boehme KW, Belko J, Latz E, Golenbock DT, Finberg RW, J Virol 2003 77 4588 4596 10.1128/JVI.77.8.4588-4596. 2003 12663765 (Pubitemid 36402808)
19. Exploitation of cellular signaling and regulatory pathways by human cytomegalovirus. Fortunato EA, McElroy AK, Sanchez I, Spector DH, Trends Microbiol 2000 8 111 119 10.1016/S0966-842X(00)01699-1 10707064 (Pubitemid 30155486)
20. p38 MAPK and NF-kappa B collaborate to induce interleukin-6 gene expression and release. Evidence for a cytoprotective autocrine signaling pathway in a cardiac myocyte model system. Craig R, Larkin A, Mingo AM, Thuerauf DJ, Andrews C, McDonough PM, Glembotski CC, J Biol Chem 2000 275 23814 23824 10.1074/jbc.M909695199 10781614 (Pubitemid 30624667)
21. Inflammation meets cancer, with NF-kappaB as the matchmaker. Ben-Neriah Y, Karin M, Nat Immunol 2011 12 715 723 21772280
22. Manifestations of human cytomegalovirus infection: proposed mechanisms of acute and chronic disease. Britt W, Curr Top Microbiol Immunol 2008 325 417 470 10.1007/978-3-540-77349-8-23 18637519
23. Seroprevalence of cytomegalovirus infection in the United States, 1988-1994. Staras SA, Dollard SC, Radford KW, Flanders WD, Pass RF, Cannon MJ, Clin Infect Dis 2006 43 1143 1151 10.1086/508173 17029132 (Pubitemid 44632796)
24. Multiple infections and subsequent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Smieja M, Gnarpe J, Lonn E, Gnarpe H, Olsson G, Yi Q, Dzavik V, McQueen M, Yusuf S, Circulation 2003 107 251 257 10.1161/01.CIR.0000044940.65226.1F 12538424 (Pubitemid 36135220)
25. The influence of latent viral infection on rate of cognitive decline over 4 years. Aiello AE, Haan M, Blythe L, Moore K, Gonzalez JM, Jagust W, J Am Geriatr Soc 2006 54 1046 1054 10.1111/j.1532-5415.2006.00796.x 16866674 (Pubitemid 43992540)
26. Cytomegalovirus infection and the risk of mortality and frailty in older women: a prospective observational cohort study. Wang GC, Kao WH, Murakami P, Xue QL, Chiou RB, Detrick B, McDyer JF, Semba RD, Casolaro V, Walston JD, Fried LP, Am J Epidemiol 2010 171 1144 1152 10.1093/aje/kwq062 20400465
27. The story of human cytomegalovirus and cancer: increasing evidence and open questions. Michaelis M, Doerr HW, Cinatl J, Neoplasia 2009 11 1 9 19107226
28. Cytomegalovirus hepatitis in normal and immune compromised hosts. Ten Napel HH, Houthoff HJ, The TH, Liver 1984 4 184 194 6087073 (Pubitemid 14088671)
29. Does cytomegalovirus play a causative role in the development of various inflammatory diseases and cancer? Soderberg-Naucler C, J Intern Med 2006 259 219 246 10.1111/j.1365-2796.2006.01618.x 16476101
30. HCMV microinfections in inflammatory diseases and cancer. Soderberg-Naucler C, J Clin Virol 2008 41 218 223 10.1016/j.jcv.2007.11.009 18164235
31. Modulatory effects of human cytomegalovirus infection on malignant properties of cancer cells. Cinatl J, Cinatl J, Vogel JU, Rabenau H, Kornhuber B, Doerr HW, Intervirology 1996 39 259 269 9078467 (Pubitemid 27105489)
32. The S phase of the cell cycle and its perturbation by human cytomegalovirus. Bain M, Sinclair J, Rev Med Virol 2007 17 423 434 10.1002/rmv.551 17676653 (Pubitemid 350144565)
33. Is HCMV a tumor promoter? Soroceanu L, Cobbs CS, Virus Res 2011 157 193 203 10.1016/j.virusres.2010.10.026 21036194
34. Human cytomegalovirus infection and expression in human malignant glioma. Cobbs CS, Harkins L, Samanta M, Gillespie GY, Bharara S, King PH, Nabors LB, Cobbs CG, Britt WJ, Cancer Res 2002 62 3347 3350 12067971 (Pubitemid 34651375)
35. Specific localisation of human cytomegalovirus nucleic acids and proteins in human colorectal cancer. Harkins L, Volk AL, Samanta M, Mikolaenko I, Britt WJ, Bland KI, Cobbs CS, Lancet 2002 360 1557 1563 10.1016/S0140-6736(02)11524-8 12443594 (Pubitemid 35356371)
36. High prevalence of human cytomegalovirus in prostatic intraepithelial neoplasia and prostatic carcinoma. Samanta M, Harkins L, Klemm K, Britt WJ, Cobbs CS, J Urol 2003 170 998 1002 10.1097/01.ju.0000080263.46164.97 12913758 (Pubitemid 36999620)
37. Human herpes viruses in non-melanoma skin cancers. Zafiropoulos A, Tsentelierou E, Billiri K, Spandidos DA, Cancer Lett 2003 198 77 81 10.1016/S0304-3835(03)00269-6 12893433 (Pubitemid 37289106)
38. Monocytes harboring cytomegalovirus: interactions with endothelial cells, smooth muscle cells, and oxidized low-density lipoprotein. Possible mechanisms for activating virus delivered by monocytes to sites of vascular injury. Guetta E, Guetta V, Shibutani T, Epstein SE, Circ Res 1997 81 8 16 9201022 (Pubitemid 27272977)
39. Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma. Porta C, De Amici M, Quaglini S, Paglino C, Tagliani F, Boncimino A, Moratti R, Corazza GR, Ann Oncol 2008 19 353 358 10.1093/annonc/mdm448 17962206 (Pubitemid 351201719)
40. Cytokine evaluation in liver cirrhosis and hepatocellular carcinoma. Cheng KS, Tang HL, Chou FT, Chou JW, Hsu CH, Yu CJ, Kao ST, Li TC, Hepatogastroenterology 2009 56 1105 1110 19760951
41. Impaired hepatic removal of interleukin-6 in patients with liver cirrhosis. Wiest R, Weigert J, Wanninger J, Neumeier M, Bauer S, Schmidhofer S, Farkas S, Scherer MN, Schaffler A, Scholmerich J, Buechler C, Cytokine 2011 53 178 183 10.1016/j.cyto.2010.06.013 20637651
42. Viral hepatitis C. Poynard T, Yuen MF, Ratziu V, Lai CL, Lancet 2003 362 2095 2100 10.1016/S0140-6736(03)15109-4 14697814 (Pubitemid 38035201)
43. Genetic polymorphisms of interleukin-6 modulate fibrosis progression in mild chronic hepatitis C. Falleti E, Fabris C, Vandelli C, Colletta C, Cussigh A, Smirne C, Fontanini E, Cmet S, Minisini R, Bitetto D, et al. Hum Immunol 2010 71 999 1004 10.1016/j.humimm.2010.06.006 20655350
44. IL-6 -174G/C polymorphism and IL-6 serum levels in patients with liver cirrhosis and hepatocellular carcinoma. Giannitrapani L, Soresi M, Giacalone A, Campagna ME, Marasa M, Cervello M, Marasa S, Montalto G, Omics 2011 15 183 186 10.1089/omi.2010.0093 21329460
45. Interleukin 6 promoter polymorphisms influence the outcome of chronic hepatitis C. Cussigh A, Falleti E, Fabris C, Bitetto D, Cmet S, Fontanini E, Bignulin S, Fornasiere E, Fumolo E, Minisini R, et al. Immunogenetics 2011 63 33 41 10.1007/s00251-010-0491-7 21072509
46. Multiple regulatory elements in the interleukin-6 gene mediate induction by prostaglandins, cyclic AMP, and lipopolysaccharide. Dendorfer U, Oettgen P, Libermann TA, Mol Cell Biol 1994 14 4443 4454 8007951 (Pubitemid 24196793)
47. Transactivation by NF-IL6/LAP is enhanced by phosphorylation of its activation domain. Trautwein C, Caelles C, van der Geer P, Hunter T, Karin M, Chojkier M, Nature 1993 364 544 547 10.1038/364544a0 8336793 (Pubitemid 23273102)
48. Signal transduction by tumor necrosis factor and gene regulation of the inflammatory cytokine interleukin-6. Vanden Berghe W, Vermeulen L, De Wilde G, De Bosscher K, Boone E, Haegeman G, Biochem Pharmacol 2000 60 1185 1195 10.1016/S0006-2952(00)00412-3 11007957
49. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, Karin M, Science 2007 317 121 124 10.1126/science.1140485 17615358 (Pubitemid 47056470)
50. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F, Biochem J 2003 374 1 20 10.1042/BJ20030407 12773095 (Pubitemid 37046923)
51. Selectivity and therapeutic inhibition of kinases: to be or not to be? Ghoreschi K, Laurence A, O'Shea JJ, Nat Immunol 2009 10 356 360 10.1038/ni.1701 19295632
52. Liver regeneration 4: transcriptional control of liver regeneration. Taub R, Faseb J 1996 10 413 427 8647340
53. Effect of VEGF and VEGF Trap on vascular endothelial cell signaling in tumors. Lassoued W, Murphy D, Tsai J, Oueslati R, Thurston G, Lee WM, Cancer Biol Ther 2011 10 1326 1333 21079419
54. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Calvisi DF, Ladu S, Gorden A, Farina M, Conner EA, Lee JS, Factor VM, Thorgeirsson SS, Gastroenterology 2006 130 1117 1128 10.1053/j.gastro.2006.01.006 16618406
55. Interleukin-6 inhibits transforming growth factor-beta-induced apoptosis through the phosphatidylinositol 3-kinase/Akt and signal transducers and activators of transcription 3 pathways. Chen RH, Chang MC, Su YH, Tsai YT, Kuo ML, J Biol Chem 1999 274 23013 23019 10.1074/jbc.274.33.23013 10438468 (Pubitemid 29388045)
56. Reduced lymphocyte infiltration during cytomegalovirus brain infection of interleukin-10-deficient mice. Cheeran MC, Mutnal MB, Hu S, Armien A, Lokensgard JR, J Neurovirol 2009 15 334 342 10.1080/13550280903062797 19626525
57. The liver as the site of C-reactive protein formation. Hurlimann J, Thorbecke GJ, Hochwald GM, J Exp Med 1966 123 365 378 10.1084/jem.123.2.365 4379352
58. Proinflammatory cytokines in CRP baseline regulation. Eklund CM, Adv Clin Chem 2009 48 111 136 19803417
59. In vitro mutation artifacts after formalin fixation and error prone translesion synthesis during PCR. Quach N, Goodman MF, Shibata D, BMC Clin Pathol 2004 4 1 10.1186/1472-6890-4-1 15028125 (Pubitemid 38767504)
60. Vaccine prevention of maternal cytomegalovirus infection. Pass RF, Zhang C, Evans A, Simpson T, Andrews W, Huang ML, Corey L, Hill J, Davis E, Flanigan C, Cloud G, N Engl J Med 2009 360 1191 1199 10.1056/NEJMoa0804749 19297572
61. Incidence of cytomegalovirus infection among the general population and pregnant women in the United States. Colugnati FA, Staras SA, Dollard SC, Cannon MJ, BMC Infect Dis 2007 7 71 10.1186/1471-2334-7-71 17605813 (Pubitemid 47162170)